Haemonetics (NYSE:HAE) Trading Down 6.2% – What’s Next?

Haemonetics Corporation (NYSE:HAE)’s stock price traded down 6.2% during mid-day trading on Tuesday . The stock traded as low as $78.69 and last traded at $77.74. 197,216 shares were traded during mid-day trading, a decline of 61% from the average session volume of 510,540 shares. The stock had previously closed at $82.92.

Key Stories Impacting Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Closed acquisition of Vivasure expands Haemonetics’ portfolio into next‑generation percutaneous vessel‑closure devices, strengthening product pipeline and M&A‑driven growth thesis. Haemonetics Acquires Vivasure Medical
• Positive Sentiment: Analyst upgrade momentum: Barrington raised its price target to $93 with an “outperform” rating, signaling upside vs. current levels and providing analyst support for the stock. Barrington price target raise
• Positive Sentiment: Company fundamentals and guidance are constructive — recent quarterly beat and FY‑2026 EPS guidance (previously communicated) have improved the valuation story and prompted commentary about re‑rating HAE. How Recent Moves Are Rewriting The Haemonetics Story
• Neutral Sentiment: J.P. Morgan conference presentation transcript reiterated strategy and commercial priorities but contained no material surprise to materially change near‑term financials. J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Analyst coverage is broadly constructive but mixed in pace — data aggregators show several buy/outperform calls alongside more cautious views, so consensus is improving but not unanimous. Where Haemonetics Stands With Analysts
• Negative Sentiment: Deal cost and contingent payments: the Vivasure acquisition price (up to ~€185M including earnouts) increases near‑term cash outflow and integration risk, which can pressure free cash flow and weigh on the multiple until synergies are proven. Haemonetics to pay up to €185M for Vivasure
• Negative Sentiment: Market reaction: elevated trading volume and the stock’s pullback suggest profit‑taking and short‑term re‑rating risk despite positive fundamentals — investors appear focused on near‑term cash and execution risk post‑deal. Orchestra BioMed to Receive Up to $21M

Analysts Set New Price Targets

Several equities research analysts have weighed in on HAE shares. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a report on Monday, December 15th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Robert W. Baird upped their price objective on shares of Haemonetics from $87.00 to $99.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Mizuho raised their target price on shares of Haemonetics from $75.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Finally, Raymond James Financial restated an “outperform” rating and issued a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Stock Performance

The business’s 50-day moving average price is $78.31 and its 200-day moving average price is $65.92. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The stock has a market cap of $3.69 billion, a PE ratio of 23.03, a P/E/G ratio of 1.55 and a beta of 0.29.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the prior year, the company posted $1.12 earnings per share. Haemonetics’s revenue for the quarter was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Haemonetics

Several institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Haemonetics during the first quarter worth $216,000. United Services Automobile Association purchased a new stake in shares of Haemonetics during the first quarter valued at $212,000. Empowered Funds LLC increased its position in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.